Well, I'm not an expert, but the results appear to be consistent with a failed trial. I'm not otherwise certain what you want us to say.
I'm not super well-versed on this drug's history, but whether the warning signs were present during Phase 2 bears examination. Often, only with the larger sample sizes of Phase 3 do trends between treatment groups become significant.
Whether this is a failed compound or a failed mechanism is a more interesting question, which I don't think any of us yet have the data to answer.
That's science, boys and girls. Really expensive science.